IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide to target T cells that recognize epitopes derived from Arginase 1, which is an immunoregulatory enzyme highly expressed in difficult-to-treat tumors associated with high levels of myeloid-derived suppressor cells, including renal cell carcinoma, head and neck, breast, pancreatic, ovarian, colorectal, and prostate cancers. In addition, the company develops IO170, a TGFß1 vaccine for the treatment of solid tumors. IO Biotech, Inc. was incorporated in 2014 and is based in Copenhagen, Denmark. Show more

Location: Ole MaalOees Vej 3, Copenhagen, 2200, Denmark | Website: https://www.iobiotech.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

115.3M

52 Wk Range

$0.66 - $2.79

Previous Close

$1.75

Open

$1.77

Volume

905,542

Day Range

$1.72 - $1.84

Enterprise Value

94.86M

Cash

28.13M

Avg Qtr Burn

-20.83M

Insider Ownership

0.36%

Institutional Own.

63.84%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.